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ABSTRACT
Controversy always existed on the utility of chemically induced mouse mammary 
carcinogenesis models as valid equivalents for the study of human breast cancer. Here, 
we performed whole exome and RNA sequencing on long latency mammary tumors (218 
± 27 days) induced by the carcinogen 7,12-Dimethylbenzathracene (DMBA) and short 
latency tumors (65 ± 11 days) induced by the progestin Medroxyprogesterone Acetate 
(MPA) plus DMBA in CD2F1 mice. Long latency tumors displayed a high frequency of 
Pi3kca and/or Pten mutations detected in 11 of 13 (85%) long latency cases (14/22, 
64% overall). Eighty-two percent (9/11) of tumors carried the Pik3ca H1047L/R hot-
spot mutation, as frequently found in human breast cancer. These tumors were luminal-
like and mostly ER/PR+, as in humans. Transcriptome profiling indicated a significant 
activation of the PI3K-Akt pathway (p=3.82e-6). On the other hand MPA+DMBA induced 
short latency tumors displayed mutations in cancer drivers not commonly found mutated 
in human breast cancer (e.g. Hras and Apc). These tumors were mostly basal-like and 
MPA exposure led to Rankl overexpression (60 fold induction) and immunosuppressive 
gene expression signatures. In summary, long latency DMBA induced mouse mammary 
tumors reproduce the molecular profile of human luminal breast carcinomas representing 
an excellent preclinical model for the testing of PIK3CA/Akt/mTOR pathway inhibitory 
therapies and a good platform for the developing of additional preclinical tools such as 
syngeneic transplants in immunocompetent hosts.
INTRODUCTION
Chemically induced rodent models of mammary 
cancer have been extensively used over the years to emulate 
human breast carcinogenesis. All models in mice and 
rats have specific advantages and limitations. Mammary 
tumors can be induced in susceptible rat strains after single 
doses of carcinogens such as DMBA or nitrosomethylurea 
(NMU). Rat tumors are not extremely invasive beyond the 
mammary fat pad, have short latency, seldom metastasize 
and are highly hormone-dependent and for that reason 
were widely used as models of estrogen dependent breast 
cancers [1]. On the other hand most mouse strains are far 
more resistant than rats to chemical induced mammary 
gland carcinogenesis, typically requiring multiple doses of 
carcinogens such as DMBA and developing only after a 
long latency. Three decades ago, it was reported that the 
progestin medroxyprogesterone acetate (MPA) at very 
high doses was carcinogenic in the mouse mammary gland 
[2]. In 1996 we observed that in our hands MPA was not 
carcinogenic per se but in combination with DMBA mouse 
mammary tumors developed with a much shorter latency 
and requiring a lower number of DMBA doses [3].
In terms of the molecular profiles of chemically 
induced mammary tumors in rodents, not much has been 
learned beyond the early work of Barbacid and coworkers 
demonstrating the signature activation of the Hras oncogene 
in NMU induced rat tumors [4, 5]. Hras activation was also 
reported but with less frequency in DMBA induced tumors 
both in rats and mice [6–8]. Since HRAS activation is very 
uncommon in human breast cancer the lingering question 
always remained on how useful were the chemically 
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induced mammary cancers in rodents as models to study the 
molecular biology of human breast cancer.
To the best of our knowledge no study to date 
has analyzed comprehensively the mutational profile of 
chemically induced mouse mammary tumors in order 
to understand how closely these models reproduce 
human breast cancer molecular profiles. To this end we 
comprehensively analyzed the mutational and transcriptomic 
profile of DMBA and MPA-DMBA induced mouse 
mammary tumors by means of exome and RNA sequencing.
RESULTS AND DISCUSSION
High mutation rates in short latency 
MPA+DMBA induced mouse mammary tumors
Exome-Seq data on 22 mouse mammary tumors 
indicated a median of 75% targeted genome loci having 
at least 40X coverage. Overall we identified 25898 single 
base substitutions including 18104 non-synonymous 
single nucleotide variants (SNVs), 6068 synonymous, 
1674 stop-gain and 52 stop-loss SNVs (Supplementary 
Data 1). We also detected 152 frameshift deletions, 135 
frameshift insertions, and 145 non-frameshift deletion/
insertion events (Supplementary Data 2).
Almost 64% of the SNVs were A>T:T>A 
transversions followed by 16% of G>T:C>A substitutions. 
These data are in agreement with previous studies 
demonstrating that A>T:T>A and G>T:C>A transversions 
were the most predominant types of base pair substitutions 
(44% and 24% respectively) induced by DMBA in rat 
mammary tissue [9]. Mutational signature analysis 
allowed us to identify a highly significant 5'-flanking 
cytidine bias and 3'-flanking cytidine/guanosine bias for 
A>T transversions in the DMBA-induced tumors (Figure 
1A). Addition of MPA treatment to the DMBA protocol 
appears to slightly modify the overall DMBA mutational 
signature increasing the frequency of G>T transversions 
in a 5'-CGG-3' context compared with DMBA treatment 
alone (p=0.033, Figure 1A).
The total mutation rate across tumors was 21.7 
mutations per Mbp on average with a range of 9.8 to 
57.7 mutations per Mbp, indicating that some mouse 
mammary tumors have significantly higher mutation rates 
than others. In this sense, MPA+Dx4 (see Methods for 
nomenclature of treatment groups) derived tumors showed 
a statistically significant increased rate of mutations/
Mbp compared with Dx4 and MPA+Dx2 derived tumors 
(p<0.001, Figure 1B). More importantly, the highest 
mutation rate (average of 30 ± 9 mutations/Mbp) was 
identified in short latency tumors (< 100 days for tumor 
Figure 1: Mutational profiles of chemically induced mouse mammary tumors. A. Mutational signature of DMBA alone and 
MPA+DMBA combined treatment. The mutational signature is displayed using a 96 substitution classification defined by the substitution 
class and the sequence context immediately 5’ and 3’ to the mutated base. The probability bars for each of the six types of substitutions as 
well as the mutated bases are displayed in different colors. Y-axis represent the percentage of mutations attributed to a specific mutation type 
corrected by the frequency of its corresponding trinucleotide across the mouse genome. B. Comparison of mutation rates per Mgbp among 
treatments. Note the much higher mutation rate found in MPA+Dx4 generated tumors. C. Correlation analysis of mutations per Mgbp and 
tumor latency in days among tumors. All but one of the short latency tumors were generated by the MPA+Dx4 protocol (red dots).
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development with an average of 65 ± 11 days), almost all 
these tumors derived from the MPA+Dx4 treatment group 
(red dots in Figure 1C).
Specific cancer driver genes mutation profiles 
differentiate short vs. long latency tumors
All tumors displayed mutations affecting multiple 
targets described as cancer driver genes or potential drivers 
as defined by the COSMIC Cancer Gene Census [10]. Due 
to space limitations in Figure 2A we display only cancer 
driver genes that were found mutated in a minimum of two 
tumors. Among these, we detected mutations affecting Pten 
in 12 of 22 (55%), Pik3ca in 11 of 22 mammary tumors 
(50%), Hras in 7 of 22 (32%), Mll3 in 7 of 22 (32%) and 
others such as Nim, Atrx, and Ptprc in 5 of 22 each one (i.e. 
23% of cases mutated for each gene) and Apc, Trp53, Irf4 
and Col2a1 were found mutated in 18% of cases each one 
(4 of 22 of cases mutated for each gene). Interestingly, we 
identified a very distinct pattern on the mutational profile 
of cancer drivers genes clearly differentiating tumors that 
develop with short latency from those with long latency. The 
short latency tumors (< 100 days for tumor development) 
produced mostly by the MPA+Dx4 protocol, were 
characterized by the predominant presence of mutations 
affecting the Hras oncogene in 6 of 9 (67%) of such early 
tumors (Figure 2B). Activating Hras mutations are well 
known consequences of exposure to mutagens such as 
DMBA and other polycyclic aromatic hydrocarbons that 
have predilection for generating DNA adducts resulting 
in A>T:T>A transversions as mentioned above and as 
demonstrated in multiple carcinogenesis models including 
mammary gland [9]. All of the tumors with Hras mutations 
(7 of 7 in Figure 2) presented the characteristic CAA to CTA 
mutation affecting codon 61 of Hras leading to the Q61L 
activating mutation.
On the other hand and interestingly, long latency 
tumors were characterized by a high prevalence of Pik3ca 
and Pten mutations (11 of 13 cases, 85%) and only one 
case displaying an Hras mutation (Figure 2B) (see below 
Figure 2: Cancer driver gene mutations in chemically induced mouse mammary tumors. A. Driver and co-driver mutations 
in tumor samples. Each column represents one tumor case and each row represents the number of mutations in each gene per tumor. Blue 
squares, + mutation. B. Distribution of the most prevalent driver/co-driver mutations among short (black bars) and long latency (gray 
bars) chemically induced tumors. C. The CoMEt test was employed to identify mutually exclusive events between Pik3ca/Pten and Hras 
mutations across the 22 tumors analyzed. As can be observed Pi3ca/Pten mutations frequently co-occurred in the same tumors and were 
mostly mutually exclusive with Hras mutations.
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for further discussion). In addition, we determined that 
Pik3ca and Pten mutations behave as mutually exclusive 
events with respect to Hras mutations (CoMEt p-value = 
0.031) (Figure 2C).
Effects of medroxyprogesterone on 
transcriptomic profiles associated with short 
latency tumors
Unsupervised analysis of RNA-Seq data 
demonstrates a clear segregation of normal CD2F1 
mouse mammary samples and the chemically induced 
mammary tumors (Figure 3A). In addition, mouse 
mammary tumors predominantly clustered according to 
the use or not of MPA (black boxes in first row of Figure 
3A). We observed that the intrinsic subtypes determined 
by immunohistochemistry and predicted by using the 
PAM50 gene model were significantly associated with 
each identified cluster. Ninety percent of the DMBA 
alone (Dx4) induced tumors (grey boxes in first row 
Figure 3A) were long latency tumors (9 out of 10), 
67% of which developed into luminal-like type tumors 
(Figure 3B). On the other hand, 100% of the MPA+Dx4 
induced tumors were short latency cases, 75% of which 
(6 of 8) classified as basal-like or Her2 subtypes (Figure 
3B). Immunohistochemistry analysis of ER/PR, luminal 
(CK8) and basal (CK5 and CK6) keratins expression of 
representative short and long latency tumors are shown 
in Figure 4. Long latency differentiated tumors showed 
strong ER, PR and CK8 positivity with residual CK5 
expression supporting a luminal-like subtype (Figure 4A–
4D). While the majority of ER/PR negative short latency 
tumors showed a mixed expression pattern of basal and 
luminal cytokeratins with strong reactivity of CK5 and 
CK6 and low/moderate expression of CK8 (Figure 4I–4L).
Comparative transcriptome analysis of MPA treatment 
in normal mammary epithelium and tumor samples 
subjected to combined MPA+DMBA protocols allowed us 
to identify a reduced set of 26 genes modulated by MPA 
(Figure 5A, Supplementary Data 3). Not surprisingly, the 
Rankl transcript (also known as Tnfsf11) was the most up-
regulated gene in MPA treated normal (Log2FC = 5.4; 
p<0.0001) and tumor (Log2FC = 6.1; p<0.0001) samples 
(Figure 5B). In previous studies it was demonstrated that 
MPA induces a 3000-fold increase of RANKL mRNA 
expression in mammary epithelial cells leading to the 
activation of the RANK/RANKL signaling cascade driving 
proliferation of mammary epithelial cells [11, 12]. Moreover, 
previous studies also demonstrated that progesterone triggers 
mammary proliferation via two distinct mechanisms: an 
early RANKL-independent direct mitogenic effect on PR-
positive cells followed by a wave of greater proliferation 
mediated by the paracrine effect of RANKL on PR-negative 
cells [13]. It is also known that the RANK/RANKL signaling 
pathway plays a major role not only in the development of 
normal mammary gland during pregnacy, but also has been 
Figure 3: Hierarchical clustering of normal and tumor samples based on RNA-Seq profiles. A. The first row represent 
tumors derived from DMBA (gray boxes) or MPA+DMBA combine protocols (black boxes). The second row represents long (gray boxes) 
and short latency (black boxes) tumors. The third and fourth rows represent tumors that carry Hras and Pik3ca mutations (black boxes). 
The fifth row indicates the ER and PR positive (black boxes) and negative (gray boxes) cases according to immunohistochemistry results. 
Tumor intrinsic subtypes predicted by the PAM50 gene model are highlighted in color codes in the last row. B. Intrinsic tumor subtypes 
according to latency.
Oncotarget64293www.impactjournals.com/oncotarget
identified as an important modulator of mammary stem-cell 
expansion as well as being a critical player in breast cancer 
metastasis development [14, 15].
Interestingly, functional enrichment analysis 
identified “immune response”, “cell adhesion” and 
“degradation of ECM” to be highly associated with 
the 26 MPA-modulated genes (Figure 5C). Supporting 
the functional enrichment analysis, a gene expression 
signature–based method known as ESTIMATE predicted 
decreased immune scores on MPA-DMBA induced 
tumors compare with DMBA alone (p<0.01) and normal 
tissues (p<0.001) (Figure 5D). These findings are in 
agreement by abundant literature reporting a critical role 
of progesterone in modulating immune tolerance to fetal 
development during pregnancy [16]. Progesterone actively 
affects various types of immune cells such as T and B 
cells, NK cells, macrophages and dendritic cells [17], 
mostly inhibiting activation, differentiation and motility 
of the various immune cell types. Furthermore, it has 
been shown that progesterone induces the differentiation 
of T cells into immune-suppressive T regulatory cells 
(Tregs) [18] and in turn activated Tregs are known to 
be critical in the development of a tumor-associated 
immunosuppressive phenotype [19]. Importantly it has 
been recently demonstrated that MPA (Depo-Provera™) 
suppresses innate and adaptive immune mechanisms, 
including inhibiting the production of INFG and IL-2, IL-
4, IL-6, IL-12, TNFα, MIP-1α and various other cytokines 
in circulating blood mononuclear cells and activated T 
cells, and these dramatic immunosuppressive effects were 
associated with the increase of HIV infections in patients 
receiving MPA as contraceptive [20].
Taken together, the present study suggests that MPA 
treatment accelerates mammary tumorigenesis in this and 
other rodent mammary tumor models via Rankl-mediated 
proliferative expansion of the DMBA ‘initiated’, e.g. 
Hras or Apc mutated mammary epithelial cells, via direct 
and paracrine mechanisms while additionally favoring 
Figure 4: Representative validation of estrogen receptor alpha (ER), progesterone receptor (PR) and luminal and 
basal cytokeratins (CKs) in mouse mammary tumors. Panels A-D. representative immunohistochemistry results for long latency 
(254 ds) tumor T12800. Carcinoma with acinar/glandular differentiation displaying strong ER and PR positivity (brown nuclei in A and B 
respectively), Strongly positive for luminal CK8 (C) and residual expression in myoepithelial like cells for CK5 (D). This tumor displayed 
mutations in Pik3ca and Pten driver genes as per Exome-Seq analyses. Panels E-F. short latency (60 ds) tumor T12513. This luminal 
carcinoma displayed mostly glandular differentiation, strong reactivity for ER, PR and CK8 (E-G. respectively) and negative for CK5 H. 
Exome-Seq for this case revealed mutations on Hras and Atm among other potential cancer driver genes. Panels I-L. Short latency (55 ds) 
adenosquamous carcinoma T12521, negative for ER (I) and PR (not shown) expression and with mixed expression of luminal (CK8) and 
basal cytokeratins CK6/CK5 that strongly stained the squamous differentiated regions.
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Figure 5: Transcriptomic changes induced by medroxyprogesterone in normal mammary gland and mammary 
tumors. A. Venn diagram illustrating the identification of a MPA 26-gene expression signature commonly deregulated in normal and 
tumors samples. B. Functional Gene Ontology enrichment analysis of the MPA-26 gene expression signature. C. Box plot of Rankl mRNA 
expression levels comparing normal and chemically induced mouse mammary tumors by the various treatment protocols as indicated at 
the bottom of D. Note the dramatic increase in Rankl expression in normal and tumor samples exposed to MPA treatment. D. Comparative 
immune scores as determined by the ESTIMATE algorithm of normal and tumor samples of various carcinogenesis protocols as indicated. 
As can be observed carcinogenesis protocols employing MPA treatment (M+Dx4 and M+Dx2) displayed significantly lower immune 
scores compared with DMBA alone and normal samples (p<0.001).
the development of an immunosuppressive (anergic) 
microenvironment that facilitates the expansion of the 
highly proliferative cells ultimately leading to the rapid 
development of mammary tumors (i.e. short-latency tumors).
High incidence of Pik3ca and Pten mutations are 
characteristics of long latency mammary tumors
As mentioned above, we detected Pik3ca and/or 
Pten mutations in 64% (14 of 22) of the mammary tumors 
analyzed. However, we observed that long latency tumors 
(>100 days for tumor development, Figure 1C), mostly 
derived from the Dx4 treatment group, were characterized 
by bearing most of the Pik3ca and/or Pten mutations (11 
of 13 long latency tumors, 85%), contrasting with the 
short latency tumors characterized by carrying Hras driver 
mutations (67%) (Figure 2A, 2B).
Originally, PIK3CA and PTEN mutations were 
thought to be mutually exclusive in various cancers with 
the exception being endometrial tumors where coexistent 
mutations of both genes were reported [21, 22]. However 
in later reports analysis of PIK3CA mutation and PTEN 
protein loss in breast carcinomas showed that both 
alterations were indeed not mutually exclusive indicating 
that PIK3CA mutations coexist with PTEN loss in ER + 
breast cancers [23]. In agreement with those observations in 
our study we detected that indeed Pik3ca and Pten behave 
as co-occurring mutations in the chemically induced mouse 
mammary tumors analyzed (p=0.003, Figure 2C).
Fifty percent of the tumors with Pten alterations 
involved non-synonymous substitution (5 of 12) and 
frameshift insertion (1 of 12) resulting in stop-gain 
mutations, the remaining cases (6 of 12) consist in 
deleterious Pten mutations leading to loss-of-function as 
was predicted by the SIFT algorithm.
The comparative frequency of mutations on the 
Pik3ca gene in our chemically induced mouse mammary 
tumors and in human invasive breast carcinomas (data 
obtained from TCGA project, http://www.cbioportal.
org/) [24] is shown in Figure 6. These results are 
revealing, indicating that 82% (9 out of 11) of DMBA-
induced tumors carried exactly the same initiating ‘hot-
spot’ mutation in Pik3ca (H1047L/R), which is by far 
the most frequent PIK3CA mutation reported in human 
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Figure 6: Comparative analysis of the frequency of Pik3Ca/PIK3CA hot-spot mutations among chemically induced 
mouse mammary tumors and human breast carcinomas. PIK3CA mutational profile in primary breast carcinomas was obtained 
from the TCGA-BRCA project [24].
invasive breast carcinomas (138 out of 349 identified 
mutations, 39.5%). Furthermore, the H1047R mutation 
was demonstrated to activate PI3K signaling in human 
mammary epithelial cells and induces tumor formation in 
nude mice [25].
We consider this a very significant finding 
considering that PIK3CA somatic mutations are detected 
in over 34% of human breast cancers and there is a need 
for pre-clinical mouse mammary cancer models that 
more closely reproduce the histology and biology of the 
human counterparts for the in vivo testing of anti-PIK3CA 
therapies [reviewed in 26].
Transcriptomic analysis of long latency 
mammary tumors revealed an activated PI3K-
Akt signaling pathway
RNA-Seq analysis revealed a group of 3675 
differentially expressed genes (FDR < 0.001; logFC > 
1, Supplementary Data 3) between normal samples and 
DMBA (Dx4) induced mammary tumors. Interestingly, 
genes associated with the Dx4 long latency mammary 
tumors were strongly related to the modulation of the 
PI3K-Akt pathway (98 related genes; p=3.82e-6), Focal 
adhesion (64 genes, p=4.98e-6), ECM-receptor interaction 
(45 genes, p=1.70e-12), PPAR signaling pathway (33 
genes; p=2.03e-6), p53 signaling pathway (27 genes, 
p=2.26e-5) and metabolic processes (Figure 7A). Among 
the 98 PI3K-Akt related genes, 39 were up-modulated 
transcripts and 59 were down-modulated transcripts in 
Dx4 induced tumors (Figure 7B). More importantly, 
several of these genes (23 out of 39) were specifically 
associated with cell cycle and cell survival PI3K-Akt 
mediated activity through up-modulation of cytokine-
receptor interactions, signal transducers (Pik3r3 over-
expression, Pik3ca and Pten mutations) and multiple 
downstream effectors such as Ccnd1, Cdk4, ATF4 and 
Myb among others.
In this sense, Spp1 (also know as Osteopontin, 
Opn) was the top up-regulated gene in Dx4 induced 
tumors (log2FC = 6.85; p-adj < 0.0001). OPN is a multi-
functional cytokine that binds to cell surface receptors, 
such as CD44 and integrins, which are involved in 
immune response, cell survival, adhesion and migration. 
OPN has been previously associated with tumor 
formation, progression and breast cancer metastasis [27]. 
Recently has been demonstrated that OPN abrogation in 
breast cancer cells leads to the inhibition of cell migration 
and invasion through inhibition of PI3K-Akt-mTOR 
signaling pathway [28]. It is important to note that several 
integrins related with PI3K-Akt signaling (e.g.: Itgb4/6 
and Itga3/6/8) were also up-modulated in Dx4 chemically 
induced tumors. Together, our results suggest that the 
overexpresion of OPN, several PI3K-Akt related binding 
receptor and several down-stream modulators including 
Pik3r3, Ccnd1 and Cdk4 among others could be part of a 
positive autoregulatory loop controlling tumor growth in 
long latency chemically induced tumors.
Concluding remarks
The comprehensive molecular characterization of 
chemically induced mouse mammary tumors allowed us to 
define mutational and transcriptomic signatures driving the 
DMBA and MPA induced carcinogenic processes. Short 
latency tumors derived mostly by the MPA+Dx4 protocol, 
were characterized by high mutational burden affecting 
multiple cancer driver genes including the predominant 
frequency of mutations affecting the Hras oncogene. 
Additionally, transcriptomic analysis suggests that MPA 
exposure accelerates mammary tumorigenesis not only via 
Rankl-mediated proliferative expansion of the carcinogen 
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‘initiated’ mammary epithelial cells carrying cancer driver 
mutations such as Hras activating and Apc loss of function 
mutations, but also by generating an immunosuppressive 
tumor microenvironment that likely facilitates the 
development of short-latency basal-like mammary 
tumors. On the other hand, DMBA-induced long-latency 
tumors were characterized by A>T and G>T substitutions 
frequently affecting the Pik3ca and Pten cancer driver 
genes. More importantly, 82% of the cases with Pik3ca 
missense mutations displayed the characteristic kinase 
domain H1047L/R ‘hot-spot’ activating mutation that 
has been reported as the most frequent PIK3CA mutation 
in human breast cancers. Furthermore, transcriptomic 
analysis of the DMBA induced tumors pointed to PI3K-
Akt signaling pathway activation as extremely common 
in long latency luminal-like tumors.
As recently reviewed [26], there is a need for 
Pik3ca mouse mammary tumor models that more closely 
reproduce the histology and biology of the human breast 
cancer PIK3CA mutated counterparts. Thus, the DMBA 
induced mouse mammary tumor model appears as an 
excellent system to provide a better understanding of 
Pik3ca/Pten mutant driven mammary cancer pathogenesis 
but also as a prime candidate for further developing pre-
clinical models (e.g. syngeneic transplant lines) for the 




Thirty fresh-frozen CD2F1 (BALB/c x DBA/2) 
mouse mammary normal and tumor samples were obtained 
from a tumor bank at the Aldaz lab from studies performed 
and reported 20 years ago in 1996 [3]. Briefly, a total of 
22 mammary tumors were analyzed by whole exome-seq 
and RNA-seq. Twelve of these tumors were derived from 
MPA-DMBA treatment groups, meaning that female mice 
received two implanted subcutaneous pellets of compressed 
MPA (20 mg each pellet, standard release) at 6 wks of age 
followed by either 2 or 4 doses of DMBA administered 
intragastrically (1 mg/dose) starting at week 9 and referred 
as MPA+Dx2 and MPA+Dx4 respectively. In addition 10 
mammary tumors were obtained from female mice that 
received only 4 doses of DMBA (1 mg/dose) as treatment 
(i.e. Dx4 group). All the aforementioned treatment groups, 
detailed protocols and comparative outcomes were 
previously described [3]. We also analyzed a group of 8 
normal mammary gland samples, 4 derived from 13 wk 
old female mice subjected to only MPA treatment for 4 
weeks (i.e. Normal + MPA group) and 4 derived from 13 
week old untreated female mice (i.e. Normal group). The 
tumor incidence and latency results were retrieved from the 
previously reported study [3].
Figure 7: Analysis of differentially expressed transcript in DMBA-induced mouse mammary tumors. A. Functional 
enrichment analysis of transcripts differentially expressed among DMBA-induced tumors and normal samples (p-adj < 0.001; Log2FC > 1). 
B. Heat map of 98 PI3K/AKT related genes differentially expressed between DMBA-induced tumors and normal samples. C. PI3K/AKT 
pathway diagram highlighting some of the genes mutated (stars) and up-modulated (colored boxes) in DMBA-induced mouse mammary 
tumors.
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Routine histopathologic evaluation was performed 
on all tumors by means of formalin fixation, paraffin 
embedding and hematoxylin and eosin stained sections. 
For tumor classification we followed the recommendations 
of the Annapolis consensus report for the analysis of 
mouse mammary tumors [29] (Supplementary Data 4). 
All samples were analyzed for ER and PR expression by 
immunohistochemistry (IHC) using standard procedures 
and tumors were considered positive for expression of 
either receptor when at least a minimum of 10% of the 
tumors cells demonstrated clearly detectable nuclear 
staining (Supplementary Data 4). The staining patterns of 
CK5 (PRB-160P antibody, BioLegend), CK6 (PRB-169P 
antibody, BioLegend) and CK8 (TROMA-I antibody, 
DSHB) keratins were analyzed by IHC to confirm the 
basal or luminal subtype.
Exome-seq data analysis
DNA from 22 mouse mammary tumor samples and 
two normal mouse mammary samples from strain CD2F1 
were purified using the DNeasy Blood and Tissue Kit 
(Qiagen). Only DNA samples with 260/280 ratios greater 
than 2.0 were processed for library construction using the 
SPRIworks Fragment Library Kit I (Beckman Coulter). 
Four libraries were pooled together and processed 
for exome capture using the NimbleGen SeqCap EZ 
Developer Library (110624_MM9_exome_L2R_
D02_EZ_HX1, Roche), covering ~ 54.3 Mbp of target 
sequence. 76 nt paired-end sequencing was performed 
using an Illumina HiSeq2000 platform at our Department’s 
NGS Facility. Image analysis, base-calling, and error 
calibration were performed using Illumina’s Genome 
analysis pipeline. Sequencing was performed reaching 
an average depth of 40X per sample. Sequenced 76 bp 
tags were aligned against the mouse reference genome 
(GRCm38/mm10) using BWA v0.7.3 and marked for 
duplicates using Picard v1.88 (http://picard.sourceforge.
net/). Tumors were called against normal DNA isolated 
from two wild-type CD2F1 mice. Subsequently, single-
nucleotide variants were identified using MuTect v1.1.4 
[30]. Identified variants were annotated using ANNOVAR 
[31] and Ensembl VEP (http://www.ensembl.org/Tools/
VEP) to compute the SIFT scores and VarScan software 
(http://dkoboldt.github.io/varscan/) was employed for 
indels detection. Detected somatic mutations were further 
filtered by focusing only on those genes considered cancer 
driver genes as defined by the COSMIC Cancer Gene 
Census database (http://cancer.sanger.ac.uk/census/). The 
Comet Exact Test (CoMEt) algorithm was employed to 
identify mutually exclusive mutations [32].
Mutational spectra analysis of DMBA and 
MPA+DMBA treatments was determined as previously 
described for human tumors [33]. Briefly, SNVs detected 
among 22 tumors were annotated by the 96 possible 
trinucleotide context substitutions (6 types of substitutions 
x 4 possible flanking 5' bases x 4 possible flanking 3' 
bases) and summed in each tumor according DMBA or 
MPA+DMBA groups. These counts were converted to 
per group proportions and subsequently adjusted for the 
trinucleotide frequency in the mouse genome.
RNA-seq data analysis
RNA was isolated and purified using TRIzol reagent 
(Life Technologies) and RNeasy mini kit (Qiagen). RNA 
concentration and integrity were measured on an Agilent 
2100 Bioanalyzer (Agilent Technologies). Only RNA 
samples with RNA integrity values (RIN) over 8.0 were 
considered for subsequent analysis. mRNA from normal 
mouse mammary and tumor samples were processed 
for directional mRNA-seq library construction using 
the ScriptSeq v2 RNA-Seq Library Preparation Kit 
(Epicentre) according to the manufacturer's protocol. 
We performed 76 nt paired-end sequencing using an 
Illumina HiSeq2000 platform and obtained ~23-37 
million tags per sample. The short sequenced reads 
were mapped to the mouse reference genome (mm10) 
by the splice junction aligner TopHat V2.0.10 [34]. We 
employed several R/Bioconductor packages to accurately 
calculate the gene expression abundance at the whole-
genome level using the aligned records (BAM files) and 
to identify differentially expressed genes between normal 
CD2F1 mouse mammary samples and the chemically 
induced mammary tumors [35]. Briefly, the number 
of reads mapped to each gene based on the TxDb.
Mmusculus.UCSC.mm10.KnownGene database were 
counted, reported and annotated using the Rsamtools, 
GenomicFeatures, GenomicAlignments, and org.Mm.eg.
db libraries. Raw datasets have been submitted to NCBI 
GEO database. To identify differentially expressed genes 
between normal mammary epithelium and tumor samples, 
we utilized the DESeq2 test based on the normalized 
number of counts mapped to each gene [36]. Functional 
enrichment analyses were performed using the ClueGo 
Cytoscape's plug-in (http://www.cytoscape.org/) and the 
InnateDB resource (http://www.innatedb.com/) based 
on the list of deregulated transcripts between normal 
and mouse mammary tumors (FDR<0.001; log FC>±1). 
Data integration and visualization of differentially 
expressed transcripts were done with R/Bioconductor 
[35] and the MultiExperiment Viewer software (MeV 
v4.9) [37]. Intrinsic subtype classification of tumors into 
Luminal-like, Basal-like, Her2-enriched and Normal-
like groups was performed using the 50-gene (PAM50) 
predictor bioclassifier R script [38]. In addition, we used 
the ESTIMATE algorithm (Estimation of STromal and 
Immune cells in Malignant Tumors using Expression 
data) to infer the immune and stromal components from 
each tumor sample [39].
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